Nanyang Biologics Moves Forward with Nasdaq Listing After Major Shareholder Vote Result

Nanyang Biologics Prepares for Nasdaq Listing

In a noteworthy development in the biotechnology sector, Nanyang Biologics Pte. Ltd. (NYB), a firm backed by The9 Limited (Nasdaq: NCTY), is on a clear trajectory toward becoming a publicly traded company on the Nasdaq exchange. This advancement follows a successful shareholder vote that took place on August 19, 2026, during which the shareholders of RF Acquisition Corp II (RFAI) approved a business combination with NYB.

A Strategic Move in Biotechnology

The9 Limited, recognized globally as a diversified high-tech company, has been strategically investing in artificial intelligence-driven opportunities beyond its core gaming operations. With NYB specializing in AI-based drug discovery, this investment marks a significant step forward for The9 in expanding its portfolio into innovative health solutions.

During the extraordinary general meeting, the approval by RFAI’s shareholders signified not just confidence in NYB’s leadership but also support for the promising avenues it presents in the field of AI in healthcare. Once the merger is finalized, The9 is anticipated to hold approximately 15% to 16% of the new company, indicating a solid stake in the future of ethical and efficient drug development.

NYB's Innovative Approach

Nanyang Biologics is at the forefront of integrating advanced technology with biotechnology. Using its proprietary Vecura™ AI platform, which leverages a unique library of over one million natural compounds, NYB aims to discover novel drug candidates that conventional methodologies often overlook. This technology is particularly promising as the pharmaceutical industry continues to seek out more effective and faster methodologies for drug development.

George Lai, Chief Executive Officer of The9, commented on the recent developments, expressing optimism for both NYB and the strategic implications for The9. He highlighted that the positive outcome of the shareholder vote not only reflects the confidence in NYB's business model but also enhances The9's standing in the burgeoning AI sector.

The9's Expanding Horizons

Founded in 1999 and having been publicly listed since 2004, The9 is venturing beyond its gaming pedigree. By embracing cutting-edge technologies like AI in drug discovery through NYB, The9 establishes a diverse economic footprint that aims to redefine how value is created and shared across industries. The ongoing investment strategy positions them to capitalize on emerging trends within the health and technology spheres, responding to a global demand for innovative healthcare solutions.

As they progress towards a Nasdaq listing, both The9 and NYB are poised to unlock new possibilities that could change the landscape of biotech investments. The successful merger emphasizes the market's growing interest in tech-driven health innovations and shows how financial strategies and investor support can align to facilitate growth in the age of digital transformation.

Looking Ahead

The implications of NYB’s eventual listing on the Nasdaq are manifold, particularly for stakeholders in both The9 and the broader biotechnology sector. This journey toward public markets stands not just as a milestone for Nanyang Biologics but also acts as a beacon for future investors looking to engage with companies that are blending AI with traditional industries.

In summary, as Nanyang Biologics advances towards its Nasdaq listing, it highlights the trend of merging high-tech capabilities with the critical field of medicine, which could herald a new chapter in drug discovery and innovation. With The9’s commitment to nurturing such advancements, the stage is set for transformative developments in how we understand and address healthcare challenges.